Longest survival data ever reported in a global Phase III trial in this setting

New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.